Please login to the form below

Not currently logged in
Email:
Password:

Ipsen boosts specialty care and R&D leadership teams

Harout Semerjian and Dr Sotirios Stergiopoulos join

Ipsen Harout SemerjianIpsen has strengthened its specialty care and R&D leadership teams with the appointments of Harout Semerjian and Dr Sotirios Stergiopoulos.

Semerjian (pictured right) becomes head of specialty care, international region and global franchises, reporting to the pharma company's chief executive David Meek.

He joins from Novartis, where he spent the last 17 years in a series of oncology and specialty care-focused roles across North America, Europe and North Africa and the Middle East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

Meek said: “Harout brings extensive leadership experience in oncology and has achieved success across a diverse range of markets including the US, Europe and the Middle East.

“He will be a tremendous asset to Ipsen, particularly as we accelerate our growth across markets and strengthen our focus on specialty care and oncology.”

Ipsen Dr Sotirios StergiopoulosMeanwhile, Dr Stergiopoulos (pictured left) has been appointed as senior vice president and head of global medical affairs, reporting to R&D lead Dr Alexandre Lebeaut.

Dr Stergiopoulos moves to Ipsen from Shire, where he was vice president and head of global medical affairs for oncology, having first joined Baxalta in the same role in 2016.

Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

Dr Lebeaut said: “Sotirios brings extensive experience in directing global medical affairs strategies along with a solid expertise in oncology drug development that includes immunology drugs and targeted agents across different tumor indications.

“Sotirios will play an important role within the R&D leadership team, particularly as we continue to strengthen Ipsen's oncology portfolio.”

7th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics